ClinVar Miner

Submissions for variant NM_000102.4(CYP17A1):c.62G>A (p.Arg21Lys)

gnomAD frequency: 0.00116  dbSNP: rs61754263
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Illumina Laboratory Services, Illumina RCV000303229 SCV000360146 uncertain significance Congenital adrenal hyperplasia 2016-06-14 criteria provided, single submitter clinical testing The c.62G>A (p.Arg21Lys) variant was reported in a homozygous state in a patient with congenital adrenal hyperplasia due to 17alpha-hydroxylase/17,20-lyase deficiency (Nuzzo et al. 2009). Studies of available family members showed that the patient's unaffected mother and sister were both heterozygous for this variant. Control data are unavailable for this variant, which is reported at a frequency of 0.00298 in the European population of the 1000 Genomes Project. The evidence for this variant is limited. The p.Arg21Lys variant is therefore classified as a variant of unknown significance but suspicious for pathogenicity for congenital adrenal hyperplasia.
GeneDx RCV000488920 SCV000576975 uncertain significance not provided 2020-09-01 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 20981092, 19636199)
Invitae RCV000488920 SCV002336475 likely benign not provided 2024-01-29 criteria provided, single submitter clinical testing
Preventiongenetics, part of Exact Sciences RCV003401284 SCV004104781 uncertain significance CYP17A1-related condition 2023-07-05 criteria provided, single submitter clinical testing The CYP17A1 c.62G>A variant is predicted to result in the amino acid substitution p.Arg21Lys. This variant has been reported in the homozygous state in an individual with congenital adrenal hyperplasia due to 17-alpha-hydroxylase/17,20-lyase deficiency (Nuzzo et al. 2009. PubMed ID: 19636199). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. This variant is reported in 0.15% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/10-104597057-C-T). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.
GenomeConnect, ClinGen RCV001249435 SCV001423439 not provided Deficiency of steroid 17-alpha-monooxygenase no assertion provided phenotyping only Variant interpretted as Uncertain significance and reported on 04-29-2017 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.
Natera, Inc. RCV001249435 SCV001459690 uncertain significance Deficiency of steroid 17-alpha-monooxygenase 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.